---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-050739"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:29:42.259163+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MiMedx Q4 net sales $87M (+17% YoY); FY $321M (+20%); guides 2024 low double-digit growth

## Summary
- Net sales Q4 $87M, FY $321M, up 17% and 20% YoY respectively.
- GAAP net income Q4 $53M (incl. $40M one-time tax benefit), FY $58M.
- Adjusted EBITDA Q4 $21M, margin 24%.
- 2024 guidance: low double-digit net sales growth, adjusted EBITDA margin >20%.
- Launched EPIEFFECT wound care product; completed debt refinancing Jan 2024.

## SEC filing metadata
- accession: 0001193125-24-050739
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000119312524050739/0001193125-24-050739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000119312524050739/d801521d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-050739
- JSON: https://secwatch.observer/filing/0001193125-24-050739.json
- Plain text: https://secwatch.observer/filing/0001193125-24-050739.txt

## Key facts
- Earnings Releases
  MIMEDX GROUP, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue Fourth quarter and full year 2023 net sales of $87 million and $321 million, net income GAAP Net Income for the fourth quarter and full year 2023 of $53 million and $58 million, respectively.. Guidance reaffirmed.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: Fourth quarter and full year 2023 net sales of $87 million and $321 million
  - Net income: GAAP Net Income for the fourth quarter and full year 2023 of $53 million and $58 million, respectively.
  - Guidance: reaffirmed
  - Result: reported results
  source text: On February 28, 2024, MiMedx Group, Inc. (the “ Company ”), issued a press release (the “ Earnings Press Release ”) announcing its results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1376339/000119312524050739/0001193125-24-050739-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.